Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Ashot AvagimyanYerevan State Medical University after M. HeratsiMohammad SheibaniIran University of Medical SciencesА. И. ТрофименкоKuban State Medical UniversityEvgenii E. LysovKuban State Medical UniversityФарида Муиновна ХамидоваSamarkand State Medical UniversityAnahit Z. AznauryanYerevan State Medical University after M. HeratsiL. M. SukiasyanYerevan State Medical University after M. HeratsiKarmen SahakyanYerevan State Medical University after M. HeratsiTamara R. GevorgyanYerevan State Medical University after M. HeratsiMarina R. TatoyanYerevan State Medical University after M. HeratsiGayane L. MkrtchyanYerevan State Medical University after M. HeratsiGoharik L. MeltonyanYerevan State Medical University after M. HeratsiAnna R. PetrosyanYerevan State Medical University after M. HeratsiL. A. MartemyanovaGomel State Medical UniversityRuzanna PetrosyanLebanese American UniversityО. И. УразоваSiberian State Medical UniversityNana PogosovaNational Medical Research Centre of Cardiology after Acad. E.I. Chazov; Patrice Lumumba Peoples’ Friendship University of RussiaNizal SarrafzadeganCardiovascular Research Institute, Isfahan University of Medical Sciences
ABI
Аннотация
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now uncovering new possibilities in the field of internal medicine owing to their diverse protective effects. In the second part of the literature review, we explore potential applications of SGLT2i in hepatology, neurology, ophthalmology, and oncology, mechanisms of action of such drugs as dapagliflozin, empagliflozin, canagliflozin, etc, and their effect on different organs and systems.
Темы
Идентификаторы
Цитирования и источники
Цитирований: 0Использованных источников: 69
Показатели — AkademScholar · Скоро